Beijing Tong Ren Tang Chinese Medicine Company Limited (3613) entered into a renewed PRC distribution framework agreement with China Beijing Tong Ren Tang Group Co., Ltd. (Tong Ren Tang Holdings). Subject to Independent Shareholders’ approval at an extraordinary general meeting on 11 February 2026, the new term runs from 1 January 2026 to 31 December 2028. Under the arrangement, Tong Ren Tang Group, as a non-exclusive distributor, may purchase Chinese Medicine Products and Owned Products from the group for distribution in the PRC or for production use.

The proposed annual transaction caps under the renewed agreement are set at HK$230 million, HK$320 million, and HK$440 million for 2026, 2027, and 2028, respectively. Prices for products will be determined with reference to prevailing market rates or on a cost-plus basis for Owned Products, ensuring that the terms to Tong Ren Tang Group are no more favorable than those offered to independent third parties. The board of directors indicates that entering into this arrangement continues to align with business development interests, given Tong Ren Tang Group’s distribution network in the PRC.